Strategic approaches to reducing the substance use-related burden of disease in Canada
Open Access
- 31 October 2025
- journal article
- Published by Elsevier in The Lancet Regional Health - Americas
- Vol. 53, 101289
Abstract
No abstract availableFunding Information
- Centre for Addiction and Mental Health
- Department of Family and Community Medicine, University of Toronto
- Institute of Neurosciences, Mental Health and Addiction
- University of Toronto
- Canadian Institutes of Health Research
This publication has 9 references indexed in Scilit:
- Cannabis use patterns and comparison trends in CanadaAddiction, 2025
- The Potential Utility of GLP-1 Receptor Agonist Medications for Addiction Treatment: A Narrative Review of Clinical and Epidemiological EvidenceCurrent Addiction Reports, 2025
- The adverse public health effects of non-medical cannabis legalisation in Canada and the USAThe Lancet Public Health, 2025
- Cannabis legalization and cannabis use, daily cannabis use and cannabis-related problems among adults in Ontario, Canada (2001–2019)Drug and Alcohol Dependence, 2023
- Concurrent use of opioids and stimulants and risk of fatal overdose: A cohort studyBMC Public Health, 2022
- Time trends and associated factors of global burden due to drug use disorders in 204 countries and territories, 1990–2019Drug and Alcohol Dependence, 2022
- Crystal methamphetamine use in British Columbia, Canada: A cross-sectional study of people who access harm reduction servicesPLOS ONE, 2021
- Responding to global stimulant use: challenges and opportunitiesThe Lancet, 2019
- The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016The Lancet Psychiatry, 2018